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Background: Renal transplant candidates are at high risk of coronary artery disease (CAD). We sought to develop a
new risk score model to determine the pre-test probability of the occurrence of significant CAD in renal transplant
candidates.
Methods: A total of 1,060 renal transplant candidates underwent a comprehensive cardiovascular risk evaluation.
Patients considered at high risk of CAD (age ≥50 years, with either diabetes mellitus (DM) or cardiovascular disease
(CVD)), or having noninvasive testing suggestive of CAD were referred for coronary angiography (n = 524).
Significant CAD was defined by the presence of luminal stenosis ≥70%. A binary logistic regression model was
built, and the resulting logistic regression coefficient B for each variable was multiplied by 10 and rounded to the
next whole number. For each patient, a corresponding risk score was calculated and the receiver operating
characteristic (ROC) curve was constructed.
Results: The final equation for the model was risk score = (age × 0.4) + (DM × 9) + (CVD × 14) and for the
probability of CAD (%) = (risk score × 2) – 23. The corresponding ROC for the accuracy of the diagnosis of CAD was
0.75 (P <0.0001) in the developmental model.
Conclusions: We developed a simple clinical risk score to determine the pre-test probability of significant CAD in
renal transplant candidates. This model may help those directly involved in the care of patients with end-stage renal
disease being considered for transplantation in an attempt to reduce the rate of cardiovascular events that
presently hampers the long-term prognosis of such patients.
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It is now widely recognized that patients with any degree
of renal dysfunction are at high risk of cardiovascular
events [1], particularly due to coronary artery disease
(CAD) [2]. Therefore, for patients with advanced chronic
kidney disease (CKD) (stage V) who are considered as
candidates for renal transplantation, screening for CAD
before their inclusion on waiting lists has become a major
challenge [3]. The importance of an unmissed diagnosis of* Correspondence: luis.gowdak@incor.usp.br
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reproduction in any medium, provided the orCAD in this population is further extended even after a
successful, uneventful renal transplant, because according
to the United States Renal Data System (USRDS) [4], car-
diovascular disease (CVD) persists as the most common
cause of death (30%) in renal transplant recipients, again
due to the high prevalence of CAD.
The task of correctly ascertaining the presence of CAD
can be more overwhelming when we take into account
that there is a high prevalence of asymptomatic patients
with extensive CAD [5], that the noninvasive testing of
CAD in patients with CKD has a reported lower sensitiv-
ity/specificity than that of the general population [6], and
routine invasive diagnostic coronary angiography is a risky
[7] and costly procedure.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Society of Transplantation (AST) [8] and the European
Renal Association - European Dialysis and Transplant
Association (ERA-EDTA) [9] have established their own
guidelines for cardiovascular risk assessment among
potential kidney transplant recipients. Although they
are slightly different, both guidelines have identified three
clinical characteristics associated with an intermediate- to
high-risk probability of CAD: age ≥50 years, diabetes
mellitus (DM), and/or evidence of CVD (symptomatic
CAD, previous myocardial infarction, and/or congestive
heart failure). The discrimination between low- and high-
risk patients for CAD seems straightforward when no
clinical risk factors are present; in this scenario, low-risk
patients can safely undergo transplantation without fur-
ther cardiac evaluation [10]. According to these guidelines,
patients at intermediate-risk (by ERA-EDTA) or high-risk
(by AST) for CAD would undergo noninvasive testing,
and if the test yields a positive result, then coronary angi-
ography is warranted. Even though these guidelines have
been in use for a decade or so, their impact on the diagno-
sis of pre-transplant CAD has not been as strong as first
assumed; in fact, there is still an open discussion on what
should be the best approach to diagnose CAD in high-risk
renal transplant candidates [3].
The purpose of the present study was to develop and
validate a simple, new risk score model to determine
the pre-test probability of any renal transplant candi-
date of having significant CAD during cardiovascular
risk assessment before a patient’s inclusion on waiting
lists, based on the presence of the aforementioned risk
factors for CAD.
Patients and methods
Patient selection and study protocol
Between 1998 and 2012, 1,060 patients with chronic renal
disease stage V on maintenance hemodialysis were referred
for cardiovascular risk assessment before inclusion on
kidney transplant waiting lists. All patients underwent
a comprehensive cardiovascular risk evaluation as described
elsewhere [2]. Briefly, we obtained from all patients a
medical history and performed a physical examination
with special interest in evidence of previous and/or current
CVD. We also performed resting 12-lead electrocardi-
ography (ECG), transthoracic echocardiography (TTE),
and myocardial perfusion scanning by single-photon
emission computed tomography (SPECT) Tc99m sestamibi
after pharmacological stress with dipyridamole. Patients
considered at high risk for CAD (age ≥50 years, or diabetes
(types 1 or 2), or having CVD, such as angina, previous
myocardial infarction or stroke, left ventricular dysfunction,
or extracardiac atherosclerosis), or having noninvasive
testing suggestive of CAD (39.5% of the non-diabetic,
or without CVD), were eligible for the study. For thepurpose of this study, the definition of CVD was widened
to include other clinical presentations of atherosclerosis,
such as previous stroke or transient ischemic attacks,
peripheral artery disease (PAD), or both together. PAD
was defined by finding during physical examination an ab-
sence of the peripheral distal pulses. Intermittent claudica-
tion was not considered for the diagnosis of PAD.
Significant CAD was arbitrarily defined as luminal
stenosis ≥70% in one or more epicardial arteries by visual
estimation from two independent experts.
Following the study protocol, 524 patients fulfilled the
high-risk criteria for CAD and were further referred for
coronary angiography, therefore, comprising the study
population for the present investigation.
This study was approved by the institutional ethics
committee and conducted according to the Declaration
of Helsinki [11]. All subjects provided a signed, written
informed consent at entry into the study, and all patients
agreed with the invasive assessment using coronary
angiography. After inception, patients were treated ac-
cording to the current guidelines for treatment of pa-
tients with, or at high-risk for, CVD [12,13] including
72 patients referred for myocardial revascularization
procedures (coronary artery bypass grafting (CABG) or
percutaneous coronary intervention (PCI)). After cardiovas-
cular risk stratification, patients were referred back to the
renal transplant unit for follow-up and inclusion/exclusion
in transplant waiting lists.
Model development
To develop the risk score model, approximately 50% of
the study population was randomly selected, whereas the
remaining half of the population was used to validate
the model. Table 1 shows the main characteristics of
patients in the ‘model group’ (n = 259; 49.4%) and in
the ‘validation group’ (n = 265; 50.6%).
A binary logistic regression model was built from the set
of three clinically relevant candidate variables, namely age,
diabetes (yes/no), and overt CVD (known atherosclerotic
disease including CAD, cerebrovascular disease or PAD,
or heart failure). Findings of myocardial perfusion scan
were not considered in this model since it would defeat the
purpose of having a simple, fast, applicable, clinically-based
model, without any further testing. The logistic regression
coefficient B for each variable was multiplied by 10 and
rounded to the next whole number. For each patient, a
corresponding risk score was calculated based on the
logistic regression model and the area under the re-
ceiver operating characteristic (ROC) curve (AUCROC)
was constructed for the diagnosis of significant CAD.
Finally, the prevalence of significant CAD for each risk
score was determined, and a final linear regression
model between risk score and the probability of CAD
was calculated. All statistical analyses were performed






Age (years) 56.8 ± 8.4 55.8 ± 9.1 0.21
Male gender (%) 69.8 67.3 0.57
Caucasian (%) 65.5 69.5 0.34
Hypertension (%) 89.8 91.1 0.66
Diabetes (%) 46.7 45.7 0.86
Smoking (%) 22.4 23.0 0.92
Overweight/obesity (%) 59.2 52.8 0.14
Dyslipidemia (%) 45.9 39.0 0.13
Previous MI (%) 12.9 11.1 0.59
Angina (%) 25.5 24.2 0.76
Previous stroke (%) 12.5 11.9 0.89
PAD (%) 28.6 29.0 1.00
Heart failure (%) 10.2 13.4 0.28
Significant CAD (%) 45.1 52.4 0.10
Any CVD (%) 45.5 48.7 0.48
BMI (kg/m2) 26.1 ± 4.5 25.7 ± 4.7 0.29
SAP (mmHg) 167 ± 31 167 ± 33 0.95
DAP (mmHg) 97 ± 16 96 ± 17 0.41
Glucose level (mg%) 122 ± 64 130 ± 98 0.30
Hematocrit (mg%) 37 ± 5 36 ± 6 0.06
Cholesterol (mg%) 182 ± 47 178 ± 48 0.32
Triglycerides (mg%) 158 ± 100 161 ± 130 0.73
Creatinine (mg%) 8.7 ± 2.7 8.5 ± 2.9 0.40
Time on dialysis (months) 36 ± 37 37 ± 43 0.79
LVEF (%) 62 ± 13 61 ± 12 0.49
BMI, body mass index; CAD, coronary artery disease; CVD, cardiovascular
disease; DAP, diastolic arterial pressure; LVEF, left ventricular ejection fraction;
MI, myocardial infarction; PAD, peripheral artery disease; SAP, systolic
arterial pressure.
Table 2 Variables in the equation
Variable B SE Wald df Sig Exp(B) Score
Age 0.039 0.016 5.827 1 0.016 1.040 0.4
DM (+) 0.853 0.278 9.423 1 0.002 2.347 9
CVD (+) 1.392 0.278 25.153 1 0.0001 4.023 14
CVD, cardiovascular disease; df, degrees of freedom; DM, diabetes mellitus;
















Figure 1 ROC curve for the new risk score for predicting
significant CAD in renal transplant candidates. CAD, coronary
artery disease; ROC, receiver operating characteristic.
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version 13 (SPSS Inc, Chicago, IL, USA).
Model validation
After the model was completed, the risk score for the
remaining patients was calculated from the final model
equation based on their individual values for the risk
factors. Using this score, sensitivity and false positive
fractions were calculated for all possible threshold values,
regarding the presence of significant CAD. The AUCROC
was calculated with 95% confidence intervals.
Results
The risk score model
Table 2 shows the results of the logistic regression used
to develop the new risk score for significant CAD in renal
transplant candidates. All three variables entered the modelwith P value <0.05. The corresponding B coefficient was
used to assign a specific value as a risk score.
The final equation for the developmental model is:
Riskscore ¼ Age 0:4ð Þ þ DM 9ð Þ
þ CVD 14ð Þ ð1Þ
where age in years, DM/CVD if yes = 1
Figure 1 shows the corresponding ROC curve and Table 3
shows the AUCROC for this model.
The validation model
After establishing the new risk score model, we validated
it in a new set of renal transplant candidates. Figure 2
and Table 4 show the results of the new risk score in this
population.
Prevalence of significant CAD according to the risk score
To have a final model to predict the probability of sig-
nificant CAD based only on three clinical variables, we
determined the prevalence of significant CAD as dis-
closed by invasive angiography for each score among
renal transplant candidates. Figure 3 shows the result-
ing scatter plot for patients with different score points
Table 3 AUCROC (developmental model)
Area SE(a) Asymptotic
sig(b)
Asymptotic 95% confidence interval
Lower bound Upper bound
0.748 0.030 0.0001 0.689 0.807
AUCROC, area under the receiver operating characteristic curve; SE, standard
error; sig, significance.
Table 4 AUCROC (validation model)
Area SE(a) Asymptotic
sig(b)
Asymptotic 95% confidence interval
Lower bound Upper bound
0.696 0.032 0.0001 0.633 0.759
AUCROC, area under the receiver operating characteristic curve; SE, standard
error; sig, significance.
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Note that there is a good relationship between the score
and the probability of CAD with a regression coefficient
(R2) of 0.81 (P <0.0001).
The resulting equation for the linear model is:
Probability of CAD ¼ Risk− score 2ð Þ−23 ð2Þ
The final model
We can combine equations (1) and (2) into a single
equation to get the expected probability of any patient
with chronic renal disease stage V to have significant
CAD during cardiovascular risk assessment before renal
transplantation, as follows:
Probability of CAD ¼ f½ Age 0:4ð Þ þ DM 9ð Þ
þ CVD 14ð Þ  2g−23
ð3Þ
For example, a nondiabetic 40-year-old patient with
no evidence of CVD will have an expected probability of















Figure 2 ROC curve for the new risk score for predicting
significant CAD in a different set of renal transplant candidates
(validation population). CAD, coronary artery disease; ROC, receiver
operating characteristic.Probability of CAD ¼ 40 0:4ð Þ þ 0 9ð Þ þ 0 14ð Þ½   2f g−23
Probability of CAD ¼ 9% 6:4−11:6%ð Þ
On the other hand, a 65-year-old diabetic patient
with PAD will have an expected probability of having
significant CAD of:
Probability of CAD ¼ 65 0:4ð Þ þ 1 9ð Þ þ 1 14ð Þ½   2f g−23
Probability of CAD ¼ 75% 68:6−81:4%ð Þ
Curves for the expected probability of CAD
Based on the final model, we constructed different curves
for the expected probability of significant CAD in renal
transplant candidates according to the patient’s age, and the
presence or absence of diabetes or CVD. Figure 4 shows
those curves.
Number needed to screen
Based on previous data from our group [2], the estimated
1-year absolute risk of fatal/non-fatal major adverse car-
diovascular events (MACE) for patients with CKD stage V
is 13% for patients with CAD ≥70% and 2% for patients
with CAD <70%. Table 5 shows that, for an estimated 40%
prevalence of having significant CAD by the newly devel-
oped risk score model, the number needed to screen using
coronary angiography to identify one cardiovascular event
excess related to CAD is 25.
Discussion
In this study, we developed and validated a new, simple
risk score to predict the probability of significant CAD
among asymptomatic, potential renal transplant candi-
dates. This model was defined based on three clinical
characteristics previously identified by both the AST and
the ERA-EDTA, which indicate intermediate- to high-risk
for CAD. Using these three variables, we were able to
define a formula to easily predict the pre-test probability of
having CAD ≥70%. Moreover, we also constructed curves
for the expected probability of CAD for patients with age
ranging from 30 to 90 years according to the presence of
diabetes or CVD, or both together.
To perform this study, more than 500 renal transplant
candidates were assessed not only noninvasively but also
by coronary angiography. Owing to ethical reasons, only
patients considered ‘at risk’ for having CAD underwent















R Sq Linear = 0.806
Figure 3 Scatter plot of the probability of having significant CAD according to risk score. CAD, coronary artery disease.
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(age, diabetes, and CVD), and/or with symptoms or
noninvasive testing suggestive of ischemic heart disease.
Thus, it came as no surprise that the patients who were
considered as high-risk by clinical criteria had such a
high prevalence of CAD. For the same reason, all three
characteristics entered our model with statistical sig-
nificance. Despite this selection bias, the final model
gave us the relative strength of each variable regarding
the risk for CAD. We must emphasize that, in this model,
CVD was not only confined (as originally proposed) to the
presence of symptomatic CAD, history of a previous myo-
cardial infarction, or signs/symptoms of heart failure. We
took a more liberal approach, extending the diagnosis of
CVD as a risk factor for CAD if any other extracardiac ath-
erosclerotic disease was present, such as previous stroke or
PAD. In previous work, we showed that in high-risk renal
transplant candidates, not only were patients with diabetes
or previous myocardial infarction at higher risk of signifi-
cant CAD, but also patients with evidence of extracardiac
atherosclerosis, such as PAD [14].
Confirming the assumption that patients included in
this study were really at high-risk for CAD, the overall
prevalence of coronary stenosis ≥70% was 48.9%. Note-
worthy is the fact that we were very strict concerning the
diagnosis of CAD in the sense that only significant coron-
ary stenosis was considered in this model. The reason for
this approach versus one accepting less severe degrees ofstenosis is that we would like to identify those patients with
coronary disease more likely to benefit from myocardial
revascularization (either percutaneous or surgical) before
renal transplantation, following the current guidelines for
such an intervention [15]. The identification of less signifi-
cant CAD, although still related to cardiovascular events,
would most likely prompt clinicians to start cardioprotec-
tive drugs, such as aspirin, β-blockers, and statins. Thus,
our model was devised to seek patients in whom there
would be a higher chance for significant CAD that might
lead to pre-transplant myocardial revascularization.
The usefulness of a risk score model may be illustrated
by the work of Ramanathan et al. [5] in which a smaller
sample of 97 asymptomatic, diabetic patients with a mean
age of 47 years underwent cardiac catheterization prior to
renal transplantation. The authors found a 37% overall
prevalence of any stenosis ≥70%, reaching 48% in patients
with type II diabetes. Following the current guidelines,
those patients should be referred for noninvasive testing,
and then only if positive, an invasive diagnostic procedure
would be recommended. We have previously shown that in
84 renal transplant candidates with diabetes, followed-up
for a median of 24 months, cardiac scintigraphy failed to
identify those at high-risk for future cardiovascular events
[16]. This is in agreement with the study by De Lima
et al. [2] in which 126 patients with CKD stage V on
hemodialysis, followed for a mean of 26 months, the nega-
tive predictive value of a transient or fixed defect by SPECT
Figure 4 Expected probability of having significant CAD (y-axis)
according to age (x-axis) for patients with (+) or without (−)
diabetes (DM) or cardiovascular disease (CVD). CAD, coronary
artery disease; CVD, cardiovascular disease; DM, diabetes mellitus.
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regarding cardiac events, coronary angiography was the
best predictor compared with noninvasive testing.
A different approach when screening for significant
CAD, specifically in patients with diabetic nephropathy
is to perform routine invasive coronary angiography. In a
small sample of 40 patients with CKD and type II diabetes,
Gang et al. [17] studied the value of dobutamine stress
echocardiography in detection of CAD. Almost half of the
patients had more than 70% lesion in at least one epicardial
vessel on coronary angiography; despite its high prevalence,
the sensitivity and specificity in identifying CAD wasTable 5 Number needed to screen to identify one cardiovascu
estimated prevalence of significant CADa
Prevalence of CAD
≥70% estimated









≥70% (AR = 13%)
5% 5 95 0.65
10% 10 90 1.30
15% 15 85 1.95
20% 20 80 2.60
25% 25 75 3.25
30% 30 70 3.90
35% 35 65 4.55
40% 40 60 5.20
aBased on 100 coronary angiographies. CAD, coronary artery disease; N/A, not appl47% and 95%, respectively, giving an accuracy of this
ischemia imaging modality of 72%. The authors con-
cluded that dobutamine stress echocardiography is a
poor predictor of CAD in patients with type II diabetes
being evaluated for renal transplantation and that cor-
onary angiography should be part of the cardiovascular
risk assessment in this population.
Another study by Witczak et al. [18], comprising 155
patients with a long history of diabetes and concomitant
CKD stages IV or V, found coronary stenosis ≥50% in 69
patients (45%); this resulted in 39 patients being referred
for myocardial revascularization (PCI = 17; CABG = 20;
PCI + CABG = 2). Based on the high prevalence of signifi-
cant CAD in this otherwise asymptomatic population and
the high rate of myocardial revascularization procedures,
the authors concluded and clearly stated that any patient
with diabetic nephropathy, regardless of symptoms, should
be screened for CAD with coronary angiography before
transplantation. This approach was further justified by the
demonstration made by the same group [19] that CAD
was not a risk factor for mortality in patients with diabetic
nephropathy accepted for transplantation when medically
treated and revascularized according to standard guide-
lines. Taken altogether, these data reinforce the paramount
importance of a pre-transplant diagnosis of CAD.
Contrary to the latter view, Aalten et al. [20] found that
in high-risk asymptomatic renal transplant candidates
undergoing routine non-invasive cardiac stress testing and
coronary angiography only in those with positive results,
there was no impact on the incidence of perioperative
events and, therefore, they did not recommend such a
strategy in all high-risk patients with end-stage renal
disease before renal transplantation. As the authors
themselves noted, their definition of a ‘high-risk’ pa-
tient was quite unique: patients with documented CAD
(previous myocardial infarction, PCI, or CABG), for ex-
ample, were in the same category as those with a body masslar event excess per year according to different
in Number of events in
patients with CAD















icable; AR, absolute risk.
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they did observe a reduction in the number of peri-
operative cardiac events in those previously screened
for CAD compared to a historical, unscreened control
group (3.8% versus 7.6%), due to the small number of
patients in the trial that difference did not reach statistical
significance. Finally, in our study, patients were censored by
the time a kidney transplant or a cardiovascular event had
occurred, or until the last available visit; this analysis per-
mitted examination of the long-term incidence of events in
patients with end-stage renal disease after the diagnosis
of significant CAD is made, not restricted to the peri-
transplant period.
The application of a risk score model as developed in
this study may allow clinicians to calculate the expected
pre-test probability of having significant CAD on an individ-
ual basis and, afterwards, to pursue with no additional inves-
tigation at all, to refer patients to noninvasive testing, or to
perform an invasive diagnostic procedure. We understand
that the best way to address this issue should be by applying
noninvasive testing (for instance, cardiac scintigraphy) and
to determine its accuracy for the diagnosis of CAD in differ-
ent pre-test probabilities of CAD. After that and based on
the Bayes’ theorem, we would be able to define low-,
intermediate-, and high-risk score cut-off points for CAD.
At the end, patients at both extremes of the pre-test prob-
ability (low/high) will have a very small benefit from nonin-
vasive testing due to a higher rate of false positives in low-
risk patients, or due to a higher rate of false negatives in
high-risk patients. Moreover, it will be of utmost importance
to determine the relationship between the presence of sig-
nificant CAD and the long-term occurrence of cardiovascu-
lar events. Such investigation is presently under way but
until these data are provided, at present, it can be left to
clinical discretion to perform invasive coronary angiography
based on a pre-specified pre-test probability of any given
renal transplant candidate to have significant CAD. Based
on the number needed to screen to identify one cardiovas-
cular event excess in patients with CAD, we recommend
pursuing with coronary angiography if the estimated risk
should be at least 40% by the new risk score model. In doing
this, for each 25 coronary angiographies performed we
would be able to identify one cardiovascular event related to
CAD. We should stress that, regardless of the pre-test prob-
ability of CAD, if a patient has a clear indication for invasive
coronary angiography due to symptoms or results of non-
invasive testing suggestive of CAD, then the procedure must
be carried on.
Conclusions
We developed a simple clinical risk score to determine the
pre-test probability of any renal transplant candidate of hav-
ing significant CAD during cardiovascular risk assessment
before a patient’s inclusion on waiting lists. We mustemphasize, however, that this score must only be applied to
those individuals without an unequivocal indication for cor-
onary angiography. This model aims to be a tool in helping
those directly involved in the care of patients with end-stage
renal disease being considered for transplantation in an at-
tempt to reduce the rate of cardiovascular events that pres-
ently hampers the long-term prognosis of such patients.
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